A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Daridorexant (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
- 26 Nov 2019 Planned End Date changed from 4 Nov 2019 to 4 Dec 2019.
- 26 Nov 2019 Planned primary completion date changed from 4 Nov 2019 to 4 Dec 2019.
- 30 Oct 2019 Planned End Date changed from 15 Oct 2019 to 4 Nov 2019.